Genprex
Focus: Genprex is an immunogene therapy biotech focused on gene therapy approaches for oncology indications, headquartered in Austin, TX since 2009. The company operates at early clinical stages with a concentrated pipeline in lung cancer.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Genprex
AI assessmentNot HiringNo open roles listed right now. Follow Genprex to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
quaratusugene ozeplasmid
Non Small Cell Lung CancerClinical Trials (1)
NCT05062980Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer
Phase 1/2Help build intelligence for Genprex
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.